DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2261746/biomarin-bmrn-q1-earnings-taking-a-look-at-key-metrics-versus-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2261746 Apr 24, 2024 - The headline numbers for BioMarin (BMRN) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. 0

https://www.zacks.com/stock/news/2261602/biomarin-pharmaceutical-bmrn-tops-q1-earnings-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2261602 Apr 24, 2024 - BioMarin (BMRN) delivered earnings and revenue surprises of 18.33% and 0.14%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.zacks.com/stock/news/2260399/is-a-surprise-coming-for-biomarin-bmrn-this-earnings-season?cid=CS-ZC-FT-tale_of_the_tape|earnings_surprise-2260399 Apr 23, 2024 - BioMarin (BMRN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. 0

https://www.zacks.com/stock/news/2256912/biomarin-pharmaceutical-bmrn-expected-to-beat-earnings-estimates-should-you-buy?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2256912 Apr 17, 2024 - BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. 0

https://www.zacks.com/stock/news/2247354/atara-biotherapeutics-atra-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2247354 Mar 28, 2024 - Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 8.20% and 73.91%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.zacks.com/stock/news/2230527/here-s-what-key-metrics-tell-us-about-biomarin-bmrn-q4-earnings?cid=CS-ZC-FT-fundamental_analysis|nfm-2230527 Feb 22, 2024 - Although the revenue and EPS for BioMarin (BMRN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. 0

https://www.zacks.com/stock/news/2228608/merus-n-v-mrus-expected-to-beat-earnings-estimates-can-the-stock-move-higher?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2228608 Feb 20, 2024 - Merus N.V. (MRUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. 0

https://www.zacks.com/stock/news/2227844/seeking-clues-to-biomarin-bmrn-q4-earnings-a-peek-into-wall-street-projections-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2227844 Feb 19, 2024 - Looking beyond Wall Street's top -and-bottom-line estimate forecasts for BioMarin (BMRN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023. 0

https://www.zacks.com/stock/news/2217328/gsk-gears-up-for-q4-earnings-will-it-surpass-estimates?cid=CS-ZC-FT-analyst_blog|earnings_preview-2217328 Jan 29, 2024 - We expect GSK's specialty products like Arexvy, Cabenuva, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive fourth-quarter sales performance. 0

https://www.zacks.com/stock/news/2215118/here-s-why-investors-may-bet-on-biomarin-bmrn-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2215118 Jan 24, 2024 - Here, we discuss some reasons why investing in BioMarin (BMRN) stock now may turn out to be a more prudent move than ever. 0